Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Medical cannabis shows promise for HIV-Related pain

NCT ID NCT05554146

Symptom relief Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether medical cannabis can reduce nerve pain and inflammation in people with HIV. Thirty-five adults with HIV and neuropathic pain used different ratios of THC and CBD over 14 weeks. Researchers measured changes in pain severity and blood markers of inflammation. The goal was to see if cannabis could ease symptoms without causing serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Oct 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: -\>=18 years old * Diagnosis of HIV * Fluency in English * Active certification for medical cannabis * ICD-10 diagnosis code for neuropathic pain, OR Neuropathic pain in problem list of electronic medical record, OR Neuropathic pain per medical cannabis certification form, OR Neuropathic Pain Questionnaire-Short Form\>0 Exclusion Criteria: * Inability to provide informed consent * Inability to complete 14 weeks of study visits * Medical cannabis use within 14 days of enrollment, and no medical cannabis dispensed within 30 days of enrollment * Unique pain symptoms (e.g., multiple sclerosis, rheumatoid arthritis) * Terminal illness * Current or prior psychotic disorder * Unregulated cannabis use in the past 14 days; opioid or cocaine use in the past 30 days * Dispensed opioids within 30 days * Non-steroidal anti-inflammatory use within 7 days prior to enrollment * Steroid use within the past 14 days with duration of therapy \>=21 days * COVID vaccination or booster within 14 days of screening * Active or acute cardiac disease based on clinician chart review.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence HIV infectious disease neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis HIV infections Neuropathic pain

Contacts and locations

Locations

  • Montefiore Health System

    The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.